Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pasithea Therapeutics Corp. Warrant (KTTAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: KTTAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -95.24% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.34 | 52 Weeks Range 0.01 - 0.10 | Updated Date 06/6/2025 |
52 Weeks Range 0.01 - 0.10 | Updated Date 06/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.84% | Return on Equity (TTM) -82.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6931236 |
Shares Outstanding - | Shares Floating 6931236 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Pasithea Therapeutics Corp. Warrant
Company Overview
History and Background
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. Their warrants are derivative instruments tied to the underlying common stock.
Core Business Areas
- CNS Drug Development: Focuses on developing new treatments for neurological and psychiatric disorders.
Leadership and Structure
Leadership team consists of CEO, CFO, and CSO. Organizational structure is typical for a small biotech company, with research, development, and clinical operations divisions.
Top Products and Market Share
Key Offerings
- Warrant: These warrants give the holder the right to purchase shares of Pasithea Therapeutics Corp. common stock at a specified price. The value is derived from the underlying stock price. Competitors are any other companies with outstanding warrants.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and research-intensive, with high risks and high potential rewards. There is a growing demand for treatments of CNS disorders.
Positioning
Pasithea Therapeutics Corp. is a smaller player in the CNS drug development space, focusing on innovative therapies. Their competitive advantage is based on their research and development pipeline.
Total Addressable Market (TAM)
The global market for CNS therapeutics is estimated in the hundreds of billions of dollars. Pasithea Therapeutics Corp. targets specific niches within this TAM. Its TAM is tied to how successful its pipeline is.
Upturn SWOT Analysis
Strengths
- Innovative research pipeline
- Experienced management team in CNS drug development
- Proprietary drug delivery technologies
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial outcomes
- Limited product portfolio
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline through acquisitions or licensing
- Positive clinical trial results for lead drug candidates
Threats
- Failure of clinical trials
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent expirations
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- BMY
- PFE
Competitive Landscape
Pasithea Therapeutics Corp. is a small player compared to major pharmaceutical companies. Its success depends on its innovative research and partnerships.
Growth Trajectory and Initiatives
Historical Growth: Growth of warrant is tied to performance of Pasithea Therapeutics Corp. stock.
Future Projections: Future warrant value is contingent upon success of Pasithea Therapeutics Corp.'s drug development pipeline and market conditions.
Recent Initiatives: Recent initiatives are related to drug development programs by Pasithea Therapeutics Corp.
Summary
Pasithea Therapeutics Corp. warrants are derivative securities whose value is driven by the underlying common stock. The company focuses on CNS drug development, which is a very risky and regulated industry. The success of the company depends on successful clinical trials and partnerships to fund operations. Investors in warrants should consider the inherent risks of the biotech sector and the potential for dilution.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Data
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pasithea Therapeutics Corp. Warrant
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-09-15 | CEO & Director Dr. Tiago Reis Marques M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.pasithea.com |
Full time employees 4 | Website https://www.pasithea.com | ||
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.